Merck Moved Every Japanese Keytruda Indication to a One-Minute Injection on a Single Lung Cancer Trial
One exposure trial in lung cancer carried every Japanese indication. The contest is now minutes and millilitres.
Immunotherapy
ViGNet Reported 82.55% Discrimination Predicting Immunotherapy Response in NSCLC
Findings Science read / Oncology / AI & ML ViGNet Reported 82.55% Discrimination Predicting Immunotherapy Response in NSCLC Athithi Verma · 18 August 2026 · 3 min read · Synopulse A Hong Kong Polytechnic University team reports that a network fusing whole slide pathology images with gene expression data reached 82.55% discrimination in classifying which … Read more
Biogen Secures Breakthrough Edge in Immunology with $1B Vanqua Buy
Biogen strengthens Immunology pipeline through $1B Vanqua acquisition deal.
OncoC4 merged with AcroImmune
OncoC4, a biopharmaceutical firm in its final phases of developing advanced cancer therapies, is merging with AcroImmune, a developer of immunotherapies for malignant tumors and inflammatory diseases. The merger produces first- and best-in-class immunotherapies. Drs. Yang Liu and Pan Zheng co-founded OncoC4 and AcroImmune, and they share a common shareholder base. The combined firm was … Read more